14.06.2011
MagForce Nanotechnologies AG Reports Financial Results and Company Highlights for Fiscal Year 2010
EU approval granted for NanoTherm® therapy in 27 EU countries Secured access to funding to support European product launch Commercial team in place and active in German market First NanoTherm® therapy center established at ...
10.03.2011
MagForce Nanotechnologies AG Hires Key Members of Sales and Marketing Team
Experienced commercial team prepared to launch NanoTherm® therapy for the treatment of brain tumorsPatient screening is underway and treatment of first patient expected to begin in the coming weeksBerlin, March 10, 2011 - MagForce Nanotechnologies AG (FSE:MF6), a leader in nanomedicine-based cancer ...
18.11.2010
MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum
Berlin, November 18, 2010- MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today that Dr. Peter Heinrich, CEO, will present the latest company developments and outline plans for 2011 at the Deutsches Eigenkapitalforum. The ...
17.11.2010
MagForce Selected as Winner of 2010 STEP Award in the Category Product/Technology
Prize awarded in recognition of company’s innovation and growth potentialBerlin, November 17, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer treatment, announced today that it has been selected as the 2010 recipient of the STEP award in the ...
15.11.2010
MagForce Nanotechnologies AG Announces Management Team Expansion
Key positions expand internal corporate structures and support Q1 2011 Nano-Cancer® therapy product launchAdditional commercialization positions to be filled in the coming weeksBerlin, November 15, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in the area of nanotechnology-based cancer ...
21.09.2010
MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme
Berlin, September 21, 2010- MagForce Nanotechnologies AG (FSE:MF6) announced today the publication of clinical data from a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy in patients with ...
28.06.2010
MagForce Nanotechnologies AG receives European regulatory approval for its Nano Cancer® therapy
Berlin - Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy. The official notice of regulatory approval signifies that ...
